Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-808-3 | CAS number: 110-85-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://chesar.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Endpoint summary
Administrative data
Description of key information
In a GPMT test only 1 out of 19 guinea pigs was positive (5%). Because of the questionable nature of this response, a second challenge was performed. Three of the nineteen animals exhibited clear responses; four additional animals had questionable responses. No response was seen in the ten control animals. Based on these responses in three of the nineteen animals (16%), Piperazine would be considered to be a mild sensitizer under the conditions of this study.
Piperazine was also studied in the Local Lymph Node Assay (LLNA). Groups of young adult Balb/c mice were administered piperazine at concentrations of 5, 10 and 20% (w/v). Piperazine (10%) produced a weakly positive response; a lack of effect at 20% was probably caused by local irritation and corrosion at this concentration.
Cytokine production was also studied. Mice were administered 50 μl piperazine at concentrations of 5 and 10% (w/v) on each shaved flank at days 1 and 6. At days 11, 12, and 13, daily doses of 25 μl were applied to the ears. The cytokine production was measured 13 days after initiation of treatment. Cytokine production (IFN-γ) was demonstrated, supporting that piperazine possess contact allergenic potential in mice. In the same study, piperazine failed to provoke production of IL-4 and IL-10, which are normally thought of as markers of respiratory tract allergens.
Key value for chemical safety assessment
Skin sensitisation
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (sensitising)
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (sensitising)
- Additional information:
Although in studies with exposed workers piperazine has been shown to cause occupational asthma, as indicated above, cytokine production (IFN-γ) was demonstrated, supporting that piperazine possess contact allergenic potential in mice but in the same study, piperazine failed to provoke production of IL-4 and IL-10, which are normally thought of as markers of respiratory allergens. It could therefore be questioned whether piperazine should be considered an asthmagen (causing asthma by non-immunological mechanism) rather than a respiratory allergen (causing asthma by an immunological mechanism).
Justification for classification or non-classification
According to the harmonized CLP classification, piperazine should be classified as skin sensitizer cat. 1 (H317) and respiratory sensitizer cat. 1 (H334). In view of its low potency in the GPMT, viz. 5% positive result upon first challenge and 16% upon rechallenge (at 5% intradermal induction, 50% epicutaneous induction, and 25% epicutaneous challenge) and an EC3 value of 6.7% in the LLNA, and the failure of piperazine at test levels of 5 and 10% to provoke production of IL-4 and IL-10, which are normally thought of as markers of respiratory tract allergens, it can be concluded that in these animal tests, piperazine is of low potency which would warrant classification as cat. 1B for both skin and respiratory sensitization.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)